RU2687967C2 - Энантиомеры 2-гидроксипроизводных жирных кислот - Google Patents

Энантиомеры 2-гидроксипроизводных жирных кислот Download PDF

Info

Publication number
RU2687967C2
RU2687967C2 RU2017141446A RU2017141446A RU2687967C2 RU 2687967 C2 RU2687967 C2 RU 2687967C2 RU 2017141446 A RU2017141446 A RU 2017141446A RU 2017141446 A RU2017141446 A RU 2017141446A RU 2687967 C2 RU2687967 C2 RU 2687967C2
Authority
RU
Russia
Prior art keywords
enantiomer
pharmaceutically acceptable
enzyme
2ohoa
hoch
Prior art date
Application number
RU2017141446A
Other languages
English (en)
Russian (ru)
Other versions
RU2017141446A (ru
RU2017141446A3 (enExample
Inventor
Пабло Висенте ЭСКРИБА РУИС
Мария Лаура МАРТИН
Мария Антония НОГЕРА САЛЬВА
Ксавьер БУСКЕТС КСАУБЕТ
Давид ЛОПЕС ХИМЕНЕС
Майтане ИБАРГУРЕН АЙСПИТАРТЕ
Хосе Хавьер СОТО САЛЬВАДОР
Мигель ИУС АСТИС
Original Assignee
Университат Де Лес Ильес Балеарс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университат Де Лес Ильес Балеарс filed Critical Университат Де Лес Ильес Балеарс
Publication of RU2017141446A publication Critical patent/RU2017141446A/ru
Publication of RU2017141446A3 publication Critical patent/RU2017141446A3/ru
Application granted granted Critical
Publication of RU2687967C2 publication Critical patent/RU2687967C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C07C51/493—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2017141446A 2011-10-07 2012-10-08 Энантиомеры 2-гидроксипроизводных жирных кислот RU2687967C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES201131622 2011-07-10
ES201131622A ES2401629B1 (es) 2011-10-07 2011-10-07 Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
US201261610762P 2012-03-14 2012-03-14
US61/610,762 2012-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014118123A Division RU2637937C2 (ru) 2011-10-07 2012-10-08 Энантиомеры 2-гидроксипроизводных жирных кислот

Publications (3)

Publication Number Publication Date
RU2017141446A RU2017141446A (ru) 2019-02-13
RU2017141446A3 RU2017141446A3 (enExample) 2019-02-13
RU2687967C2 true RU2687967C2 (ru) 2019-05-17

Family

ID=48043212

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017141446A RU2687967C2 (ru) 2011-10-07 2012-10-08 Энантиомеры 2-гидроксипроизводных жирных кислот
RU2014118123A RU2637937C2 (ru) 2011-10-07 2012-10-08 Энантиомеры 2-гидроксипроизводных жирных кислот

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014118123A RU2637937C2 (ru) 2011-10-07 2012-10-08 Энантиомеры 2-гидроксипроизводных жирных кислот

Country Status (12)

Country Link
US (1) US9359281B2 (enExample)
EP (2) EP3287437B1 (enExample)
JP (1) JP2014530806A (enExample)
CN (1) CN104321300A (enExample)
DK (1) DK2774910T3 (enExample)
ES (3) ES2401629B1 (enExample)
HU (1) HUE035430T2 (enExample)
IN (1) IN2014CN03111A (enExample)
PL (1) PL2774910T3 (enExample)
PT (1) PT2774910T (enExample)
RU (2) RU2687967C2 (enExample)
WO (1) WO2013050644A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
AU2015334964B2 (en) * 2014-10-21 2019-06-20 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
HUE063275T2 (hu) * 2017-05-16 2024-01-28 Ability Pharmaceuticals S A Gyógyszerészeti kombináció rákbetegség kezelésére
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
AU2021212330A1 (en) * 2020-01-29 2022-09-22 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
KR20220140723A (ko) * 2020-02-10 2022-10-18 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합
WO2024063611A2 (ko) * 2022-09-23 2024-03-28 박진병 지방산 수용체를 강하게 활성화시키는 장쇄 지방산 또는 이의 유도체
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435235A1 (en) * 2001-10-11 2004-07-07 Universitat de les Illes Balears Use of hydroxyoleic acid and similar compounds in the production of medicaments
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
WO2010066931A1 (es) * 2008-12-09 2010-06-17 Universitat De Les Illes Balears Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
WO2010106211A1 (es) * 2009-03-16 2010-09-23 Lipopharma Therapeutics, S.L Uso de derivados de ácidos grasos poliinsaturados como medicamentos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR547601A0 (en) * 2001-06-05 2001-06-28 Carcraft Qld Pty Ltd Tab with writing surface

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
EP1435235A1 (en) * 2001-10-11 2004-07-07 Universitat de les Illes Balears Use of hydroxyoleic acid and similar compounds in the production of medicaments
WO2010066931A1 (es) * 2008-12-09 2010-06-17 Universitat De Les Illes Balears Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
WO2010106211A1 (es) * 2009-03-16 2010-09-23 Lipopharma Therapeutics, S.L Uso de derivados de ácidos grasos poliinsaturados como medicamentos

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RN 1245729-88-7. Waldemar Adam et al. "Synthesis of Optically Active alfa-Hydroxy Acids by Kinetic Resolution Through Lipase-catalyzed Enantioselective Acetylation" Eur. J. Org. Chem., 1998, p. 2013-2018. *
Waldemar Adam et al. "Synthesis of Optically Active alfa-Hydroxy Acids by Kinetic Resolution Through Lipase-catalyzed Enantioselective Acetylation" Eur. J. Org. Chem., 1998, p. 2013-2018. *
база данных CAS on STN, реферат AN 153:423543, *

Also Published As

Publication number Publication date
EP2774910A1 (en) 2014-09-10
RU2017141446A (ru) 2019-02-13
IN2014CN03111A (enExample) 2015-07-03
RU2017141446A3 (enExample) 2019-02-13
CN104321300A (zh) 2015-01-28
EP3287437A1 (en) 2018-02-28
ES2401629A1 (es) 2013-04-23
RU2014118123A (ru) 2015-11-20
US9359281B2 (en) 2016-06-07
EP2774910A4 (en) 2015-02-25
ES2773784T3 (es) 2020-07-14
WO2013050644A1 (es) 2013-04-11
ES2401629B1 (es) 2014-03-04
ES2653675T3 (es) 2018-02-08
RU2637937C2 (ru) 2017-12-08
HUE035430T2 (en) 2018-05-02
DK2774910T3 (en) 2018-01-08
JP2014530806A (ja) 2014-11-20
US20140288176A1 (en) 2014-09-25
EP3287437B1 (en) 2019-12-11
EP2774910B1 (en) 2017-09-27
PL2774910T3 (pl) 2018-03-30
PT2774910T (pt) 2018-01-03

Similar Documents

Publication Publication Date Title
RU2687967C2 (ru) Энантиомеры 2-гидроксипроизводных жирных кислот
JP2014530806A5 (enExample)
KR102233102B1 (ko) 고도불포화 지방산 유도체의 의약으로서 용도
Igarashi et al. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex
JP7234151B2 (ja) 脂肪酸誘導体およびこれらの使用
JP2019142887A (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Yang et al. Cellular membrane fluidity in amyloid precursor protein processing
Borisova et al. Synthesis of new fluorinated analogs of GABA, Pregabalin bioisosteres, and their effects on [3H] GABA uptake by rat brain nerve terminals
Morito et al. Fatty acid metabolism in peroxisomes and related disorders
JP7361124B2 (ja) キャップされた３－ヒドロキシカルボン酸およびそれらの塩およびエステルの製造方法
JP2007119361A (ja) ホスホリパーゼａ２阻害剤
RU2441061C2 (ru) Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
Huguenard Characterization of Lipid Bioenergetic Markers in Alzheimer’s Disease (AD) in Apolipoprotein E4 (APOE) and non-E4 Carriers.
WO2022050355A1 (ja) ドコサヘキサエン酸、ドコサヘキサエノイル基含有ホスファチジン酸、又はその誘導体によるセロトニントランスポーター関連精神疾患の予防・治療剤
Florent-Béchard et al. Neuroprotective effects of DHA in Alzheimer’s disease models
Farooqui Neural membranes: A Pandora’s box of lipid mediators
Akbar et al. Role of omega-3 fatty acids in the brain and their signaling mechanisms
Van Study of the effects of docosahexaenoic acid (DHA) and a structured phospholipid containing DHA on physiological and pathological conditions of neurogenesis in vitro
JP2018505889A (ja) アテローム形成を治療するためのシステムおよび方法
Babenko Fish Oil n-3 Fatty Acids to Prevent Hippocampus and Cognitive Dysfunction in Experimental Alcoholism
HK1232430B (zh) 多不饱和脂肪酸的衍生物作为药物的用途
HK1232207B (zh) 多不饱和脂肪酸的衍生物作为药物的用途
WO2007039592A1 (en) Polyunsaturated fatty acids as bace inhibitors
HK1232430A1 (en) Use of derivates of polyunsaturated fatty acids as medicaments
HK1232430A (en) Use of derivates of polyunsaturated fatty acids as medicaments